La gestione dell'iperparatiroidismo secondario nella malattia renale cronica allo stadio 3 e 4

Abstract

Get full access to this article

View all access options for this article.

References

Silver

Molecular mechanisms of secondary hyperparathyroidism.

Nephrol Dial Transplant 2000; 15(Suppl 5): S2–7.

Slatopolsky

, Brown

, Dusso

Pathogenesis of secondary hyperparathyroidism.

Kidney Int 1999; 56(Suppl 73): S14–9.

Bro

, Olgaard

Effects of excess PTH on nonclassical target organs.

Am J Kidney Dis 1997; 30: 606–20.

Brown

E.M.

, Gamba

, Riccardi

. Cloning and Charaterization of an extracellular Ca2-sensing receptor from bovine parathyroid. Nature 1993; 366: 575–80.

Blacher

, Guerin

A.P.

, Pannier

, Marchais

S.J.

, London

G.M.

Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal.

Hypertension 2001; 38: 938–42.

Slagueira

Vascular calcification in the uremic patient: a cardiovascular risk?

Kidney Int 2003; 63(suppl): S119–21.

Wang

A.Y.

, Wang

, Woo

. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14: 159–68.

Parfitt

A.M.

The hyperparathyroidism of chronic renal failure: a disorder of growth.

Kidney Int 1997; 52: 3–9.

Cozzolino

, Butti

, Chiarelli

. New insights in the pathogenesis of secondary hyperparathyroidism. G Ital Nefrol 2005; 4: 329–36.

10.

Slatopolsky

, Finch

, Denda

. Phosphorus restriction prevents parathyroid gland growth. High Phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534–40.

11.

Silver

, Bar Sela

, and Naveh-Many

Regulation of parathyroid cell proliferation.

Curr Opin Nephrol Hypertens 1997; 6: 321–26.

12.

Cozzolino

, Brancaccio

, Gallieni

. Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 2005, 18(1 Il calciomimetico nell'iperparatiroidismo primitivo e se): 5–8.

13.

Cozzolino

, Dusso

, Slatopolsky

Role of calcium x phosphate product and bone associated proteins on vascular calcification in renal failure.

J Am Soc Nephrol 2001; 12: 2511–6.

14.

Cozzolino

, Brancaccio

, Gallieni

, Slatopolsky

Pathogenesis of vascular calcification in chronic kidney disease.

Kidney Int 2005; 68: 429–36.

15.

Cozzolino

, Gallieni

, Brancaccio

. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. J Nephrol 2006; 19: 566–57.

16.

Levin

, Andress

L.D.

, Molitch

. Prevalence of abnormal PTH in relation to serum calcium, phosphorus and vitamin D in patients with stage 3 and 4 Chronic Kidney Disease (CKD). JASN 2005 (Abstract Meeting ASN 2005).

17.

Kawashima

, Kraut

J.A.

, Kurokawa

Metabolic acidosis suppresses 25-hydroxyvitamin D3–1alpha-hydroxylase in the rat kidney.

J Clin Invest 1982; 70: 135–40.

18.

Nesby-O'Dell

, Scanlon

K.S.

, Cogswell

M.E.

. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr 2002; 76: 187–92.

19.

Gallieni

, Kamimura

, Ahmed

. Kinetics of monocyte 1α-hydroxylase in renal failure. Am J Physiol 1995; 268: F746–53.

20.

Liu

, Yu

W.R.

, Carling

. Regulation of gp330/megalin expression by vitamins A and D. Eur J Clin Invest 1998; 28: 100–07.

21.

Raggi

, Boulay

, Chasin-Taber

. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695–701.

22.

London

G.M.

, Guerin

A.P.

, Marchais

S.J.

. Arterial medial calcification in end-stage renal disease: impact on all cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731–40.

23.

Yildiz

, Memisoglu

, Oflaz

. Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic hemodialysis patients. Nephrol Dial Transplant 2005; 20: 760–7.

24.

Guerin

A.P.

, Blacher

, Pannier

. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103: 987–92.

25.

Blacher

, Guerin

A.P.

, Pannier

. Arterial calcifications, arterial stiffness and cardiovascular risk in endstage renal disease. Hypertension 2001; 38: 938–42.

26.

Ducy

, Zhang

, Geoffroy

. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747–54.

27.

Sjoden

, Lindgren

J.U.

, DeLuca

H.F.

Antirachitic activity of 1 alpha-hydroxyergocholecalciferol and 1 alpha-hydroxycholecalciferol in rats.

J Nutr 1984; 114: 2043–6.

28.

Gonzalez

E.A.

, Sachdeva

, Oliver

D.A.

, Martin

K.J.

Vitamin D insufficiency and deficiency in chronic kidney disease: a single center observational study.

Am J Nephrol 2004; 24: 503–10.

29.

Healy

M.D.

, Malluche

H.H.

, Goldstein

D.A.

. Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med 1980; 140: 1030–33.

30.

Coburn

J.W.

, Maung

H.M.

, Elangovan

. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004; 43: 877–90.

31.

Rix

, Andreassen

, Eskildsen

. Bone mineral density and biochemical markers of bone turnover in patients with pre-dialysis chronic renal failure. Kidney Int 1999; 56: 1084–93.

32.

National Kidney Foundation.

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Am J Kidney Dis 2003; 42(Suppl 3): S1–201.

33.

Caglar

, Yilmaz

M.I.

, Saglam

. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61–8.

34.

Sprague

S.M.

, Abboud

, Qiu

. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009; 4: 178–85.

35.

Szabo

, Merke

, Beier

. 1,25(OH)2vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049–56.

36.

Slatopolsky

, Cozzolino

, Finch

J.L.

Differential effects of 19-nor-1,25-(OH)2D2 and 1alpha-hydroxyvitamin D2 on calcium and phosphorum in normal and uremic rats.

Kidney Int 2002; 62: 1277–84.

37.

Teng

, Wolf

, Ofsthun

M.N.

. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–25.

38.

Dobrez

D.G.

, Mathes

, Amdahl

. Paricalcitoltreated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004; 19: 1174–81.

39.

Kawata

, Imanishi

, Kobayashi

. Relationship between parathyroid calcium sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol 2005; 153: 587–94.

40.

Block

, Kevin

J.M.

, De Francisco

A.L.M.

. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 627–35.

41.

Moe

S.M.

, Chertow

G.M.

, Coburn

J.W.

. Achieving NFK-K/DOQI TM bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760–71.

42.

Chonchol

, Locatelli

, Abboud

H.E.

. A randomized, double-blind, placebo-controlled study to assess the efficacy an safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 2008; Dec 23.